- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
- Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
- Sobi publishes Annual and sustainability report for 2023
- Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024
More ▼
Key statistics
On Friday, Swedish Orphan Biovitrum AB (publ) (SOBI:STO) closed at 281.00, -6.95% below its 52-week high of 302.00, set on Feb 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 277.20 |
---|---|
High | 286.80 |
Low | 269.20 |
Bid | 281.00 |
Offer | 281.00 |
Previous close | 280.80 |
Average volume | 581.57k |
---|---|
Shares outstanding | 354.36m |
Free float | 195.56m |
P/E (TTM) | 45.37 |
Market cap | 99.50bn SEK |
EPS (TTM) | 6.19 SEK |
Data delayed at least 15 minutes, as of Apr 26 2024 17:00 BST.
More ▼